目的：接受免疫检查点抑制剂（ICIs）治疗的患者中药物诱发的结节病样反应（DISR）的发生率正在上升。我们确定转移性肾细胞癌 (mRCC) 人群中 DISR 的发病率和特征。方法：我们回顾性审查了在同一机构接受免疫联合治疗的 83 名转移性肾细胞癌 (mRCC) 患者的临床放射学数据。结果：15 名患者接受了免疫双药（伊匹单抗-纳武单抗），而 68 名患者接受了其他基于免疫的组合。两例 DISR (2.4%) 得到证实，纵隔淋巴结肿大，模拟疾病进展，因此需要活检以显示 DISR 的组织学特征。结论：在我们的系列中DISR的发生率、放射学和临床特征，均与文献报道相符。 DISR 诊断通常仅是放射学诊断，其发生可能与更好的结果相关。

Aim: The incidence of drug-induced sarcoidosis-like reactions (DISR) in patients treated with immune checkpoint inhibitors (ICIs) is rising. We determine the incidence and characteristics of DISR in a metastatic renal cell carcinoma (mRCC) population. Methods: We retrospectively reviewed clinico-radiological data of 83 mRCC patients treated at a single institution with immune-based combinations. Results: 15 patients received immune-doublet (ipilimumab-nivolumab), while 68 patients received other immune-based combinations. Two cases of DISR (2.4%) were evidenced, with enlargement of mediastinal lymph nodes that mimicked disease progression, thus requiring a biopsy which showed histological features of DISR. Conclusion: In our series of the incidence of DISR, radiological and clinical features, are in line with literature. DISR diagnosis is often only radiological, and its occurrence is possibly associated with a better outcome.